Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Absolute risk

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    824 result(s) found for: Absolute risk. Displaying page 1 of 42.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002828-85 Sponsor Protocol Number: RG_15-114 Start Date*: 2017-04-28
    Sponsor Name:University of Birmingham
    Full Title: Paediatric Hepatic International Tumour Trial
    Medical condition: Hepatoblastoma and Hepatocellular Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062001 Hepatoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000191-41 Sponsor Protocol Number: GC28210 Start Date*: 2012-06-19
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE
    Medical condition: Coronary Heart Disease or High Risk of Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001846-90 Sponsor Protocol Number: MDCO-PCS-17-08 Start Date*: 2017-12-12
    Sponsor Name:The Medicines Company
    Full Title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001787-71 Sponsor Protocol Number: CCB-CRC-07-01 Start Date*: 2008-02-11
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity
    Medical condition: Adiposity is another risk factor for developing cardiac insufficiency and myocardial hypertrophy. Probably the volume loading of the left ventricle, systemic inflammation, the fatty degeneration of...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012799-28 Sponsor Protocol Number: MAF-AGN-OPH-GLA-010 Start Date*: 2009-11-11
    Sponsor Name:Allergan
    Full Title: Estudio Piloto de tres meses, multicéntrico, enmascarado para el Investigador, para evaluar la eficacia y la seguridad de una combinación fija de Bimatoprost/Timolol versus Latanoprost en pacientes...
    Medical condition: Treatment-Naïve Patients with Open Angle Glaucoma at High Risk of Glaucomatous Progression. Pacientes Naïve con glaucoma de ángulo abierto con alto riesgo de progresión glaucomatosa.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002910-39 Sponsor Protocol Number: NC19453 Start Date*: 2006-07-31
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 over a 24-week period in Patients with CHD or a CHD Risk Equivalent
    Medical condition: CHD or CHD Risk Equivalent
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002637-37 Sponsor Protocol Number: PIPACOPC3CC Start Date*: 2017-09-06
    Sponsor Name:Kirurgisk Afdeling A, Odense Universitetshospital
    Full Title: Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high risk colon cancer patients. - The PIPAC-OPC3 CC trial -
    Medical condition: Recurrence after resection for colon cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001022-22 Sponsor Protocol Number: COV-2-STs Start Date*: 2021-05-14
    Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου"
    Full Title: Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients
    Medical condition: COVID-19 high-risk patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003320-40 Sponsor Protocol Number: EP-003 Start Date*: 2023-03-14
    Sponsor Name:Empros Pharma AB
    Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001585-15 Sponsor Protocol Number: 2018-01671 Start Date*: 2020-01-30
    Sponsor Name:Centre Hospitalier Universitaire Vaudois
    Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia
    Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005828-11 Sponsor Protocol Number: SAVE-MORE Start Date*: 2020-12-16
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE-MORE DOUBLE-BLIND, RANDOMIZED, PHASE III CONFIRMATORY TRIAL
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035738 Pneumonia viral NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003943-55 Sponsor Protocol Number: MDS0706 Start Date*: 2007-09-25
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: “Clinical and biological effects of 5-Azacitidine five days/monthly schedule in symptomatic low-risk myelodysplastic syndromes (MDSs)”
    Medical condition: Adlut patients with low risk MDS (IPPS 0-1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000818-11 Sponsor Protocol Number: M-41008-48 Start Date*: 2019-09-19
    Sponsor Name:Almirall
    Full Title: Clinical study to evaluate the efficacy and safety of a combination therapy with dimethyl fumarate (DMF) and NB-UVB phototherapy (versus DMF monotherapy) in adults with moderate-to-severe chronic p...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003542-17 Sponsor Protocol Number: FISM_IRON-MDS Start Date*: 2019-05-06
    Sponsor Name:FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS
    Full Title: Early and low dose Deferasirox (3.5 mg/kg FCT) to suppress NTBI and LPI as early intervention to prevent tissue iron overload in lower risk MDS
    Medical condition: Adult patients with low risk MDS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000510-10 Sponsor Protocol Number: RG_11-141 Start Date*: 2012-10-09
    Sponsor Name:University of Birmingham
    Full Title: A Phase IIa trial of 177 Lutetium Dotatate in Children with Primary Refractory or Relapsed High-Risk Neuroblastoma
    Medical condition: Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003820-36 Sponsor Protocol Number: BAY1841788/17712 Start Date*: 2014-07-25
    Sponsor Name:Bayer AG
    Full Title: A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Medical condition: High-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) HU (Completed) FI (Completed) LV (Completed) CZ (Completed) AT (Completed) GB (Completed) SK (Completed) DE (Completed) PT (Completed) IT (Completed) BE (Completed) BG (Completed) FR (Completed) PL (Completed) RO (Completed) LT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001065-17 Sponsor Protocol Number: EXO_01 Start Date*: Information not available in EudraCT
    Sponsor Name:Fondazione IRCCS Policlinico San Matteo
    Full Title: Early treatment with evOlocumab in patients with sT-elevation myocardial Infarction undergoing primary pCi
    Medical condition: Acute myocardial infarction with persistent ST segment elevation (STEMI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004393-22 Sponsor Protocol Number: LIB003-006 Start Date*: 2022-01-13
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disea...
    Medical condition: Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002851-41 Sponsor Protocol Number: 1228.1 Start Date*: 2006-03-07
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertensi...
    Medical condition: hypertension and dyslipidaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 08:07:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA